An early release study published today in The Lancet Global Health found the typhoid conjugate vaccine, Typbar TCV®, can offer disease immunity for up to three years in children as young as nine months old.
The phase 3 research conducted in the African country of Malawi found that the TCV vaccine is safe and well tolerated.
Typhoid Vaccine Provides Multi-Year Immunity in Children
Increase in Pediatric Intracranial Abscess Cases Seen During COVID-19
Increases seen in isolated intracranial abscess and sinusitis complicated by intracranial abscess during early COVID-19 pandemic
Most Older Americans Say They Will Get Updated COVID-19 Booster in Fall
Poll suggests ~61 percent of people older than 50 years who have gotten at least one dose of vaccine say they would get an updated booster